Outer membrane porin D

Spero Therapeutics to Present Data at IDWeek 2021

Retrieved on: 
Thursday, September 16, 2021

CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 October 3, 2021.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 October 3, 2021.
  • Title: Molecular epidemiology of Escherichia coli causingurinary tract infectionsin the United States and in vitro activity of tebipenem, includingagainststrain lineage and resistant subsets (2018-2020)
    12.
  • Title: An evaluation of tebipenem in vitro activity against a panel of Pseudomonas aeruginosa isolates with Efflux, AmpC, and OprD Mutations
    14.
  • InSeptember 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.